Ardelyx reported $42.72M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 7.51B 560M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Ardelyx USD 42.72M 47.32M Sep/2025
aTyr Pharma USD 6.15M 11.07M Sep/2025
Corcept Therapeutics USD 125.14M 22.39M Sep/2025
Sanofi EUR 7.66B 1.25B Dec/2025
TG Therapeutics USD 178.32M 100.54M Sep/2025
United Therapeutics USD 1.34B 253M Sep/2025